Literature DB >> 24446275

Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases?

Felix Ceelen1, Daniel Theisen, Xabier García de Albéniz, Christoph J Auernhammer, Alexander R Haug, Melvin D'Anastasi, Philipp M Paprottka, Carsten Rist, Maximilian F Reiser, Wieland H Sommer.   

Abstract

PURPOSE: To evaluate the association of therapy-related changes in imaging parameters with progression-free survival (PFS) of patients with unresectable liver metastases from neuroendocrine tumors (NETLMs).
MATERIALS AND METHODS: Forty-five radioembolized patients (median age: 62 years; range: 43-75) received a pre- and 3 months posttherapeutic magnetic resonance imaging (MRI) examination. The latter were evaluated for tumor size, arterial enhancement, and necrosis pattern. Influences of therapy-related changes on PFS were analyzed. Statistical analysis included Student's t-test, Wilcoxon test, Cox regression analysis, and Kaplan-Meier curves.
RESULTS: The median percentage decrease in sum of diameters was 9.7% (range: 43.9% decrease to 15.4% increase). Twenty-one patients (47%) showed increased necrosis. Three parameters were associated with significantly longer PFS: a decrease of diameter (hazard ratio [HR]: 0.206; 95% confidence interval [CI]: 0.058-0.725; P = 0.0139), a decrease in tumor arterial enhancement (HR: 0.143; 95% CI: 0.029-0.696; P = 0.0160), and an increase in necrosis after 3 months (HR: 0.321; 95% CI: 0.104-0.990; P = 0.0480). Multivariate analysis revealed that changes in diameter and arterial enhancement have complementary information and are associated independently with long PFS.
CONCLUSION: A decrease both in sum of diameters and arterial enhancement of metastases, as well as an increase in necrosis, are associated with significantly longer PFS after radioembolization.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  liver metastases; neuroendocrine tumors; progression free survival; radioembolization

Mesh:

Substances:

Year:  2014        PMID: 24446275     DOI: 10.1002/jmri.24569

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  3 in total

Review 1.  Liver transarterial embolizations in metastatic neuroendocrine tumors.

Authors:  Louis de Mestier; Magaly Zappa; Olivia Hentic; Valérie Vilgrain; Philippe Ruszniewski
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

Review 2.  Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.

Authors:  Andrew Kennedy; Daniel B Brown; Jonas Feilchenfeldt; John Marshall; Harpreet Wasan; Marwan Fakih; Peter Gibbs; Alexander Knuth; Bruno Sangro; Michael C Soulen; Gianfranco Pittari; Ricky A Sharma
Journal:  J Gastrointest Oncol       Date:  2017-12

3.  Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Shunda Du; Jianjiao Ni; Linqian Weng; Fei Ma; Shaohua Li; Wenze Wang; Xinting Sang; Xin Lu; Shouxian Zhong; Yilei Mao
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.